On the public citation graph

Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives

https://doi.org/10.1093/ajh/hpaa096
0 signed · 114 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

1 of the 18 references listed on this page is in the Retraction Watch database as retracted (export 2026-10-21): 10.1056/nejmoa2007621 (notice 2020-06-04).

Dataset join, best-effort; this page does not check the publisher record. Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0); dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamacardio.2020.1624openalex-snapshot
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China
inferredcites →https://doi.org/10.1001/jamacardio.2020.1855openalex-snapshot
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)
inferredcites →https://doi.org/10.1007/s40292-020-00380-3openalex-snapshot
Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension
inferredcites →https://doi.org/10.1016/j.cell.2020.02.052openalex-snapshot
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
inferredcites →https://doi.org/10.1016/j.coph.2017.12.002openalex-snapshot
Targeting the renin–angiotensin system as novel therapeutic strategy for pulmonary diseases
inferredcites →https://doi.org/10.1016/s2213-2600(20)30116-8openalex-snapshot
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
inferredcites →https://doi.org/10.1038/nm1267openalex-snapshot
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
inferredcites →https://doi.org/10.1038/s41586-020-2012-7openalex-snapshot
A pneumonia outbreak associated with a new coronavirus of probable bat origin
inferredcites →https://doi.org/10.1056/nejmoa2002032openalex-snapshot
Clinical Characteristics of Coronavirus Disease 2019 in China
inferredcites →https://doi.org/10.1056/nejmoa2006923openalex-snapshot
Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
inferredcites →https://doi.org/10.1056/nejmoa2007621openalex-snapshot
RETRACTED: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19
inferredcites →https://doi.org/10.1056/nejmoa2008975openalex-snapshot
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
inferredcites →https://doi.org/10.1093/eurheartj/ehi114openalex-snapshot
Myocardial infarction increases ACE2 expression in rat and humans
inferredcites →https://doi.org/10.1093/europace/euw246openalex-snapshot
Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling
inferredcites →https://doi.org/10.1093/jtm/taaa041openalex-snapshot
Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19
inferredcites →https://doi.org/10.1161/circresaha.120.317242openalex-snapshot
Response by Zhang et al to Letter Regarding Article, “Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19”
inferredcites →https://doi.org/10.1161/circulationaha.104.510461openalex-snapshot
Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2
inferredcites →https://doi.org/10.1161/hypertensionaha.120.15082openalex-snapshot
Renin-Angiotensin System Blockers and the COVID-19 Pandemic

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3684465openalex-extracted
RAAS Blockers and Region-Specific Variations in COVID-19 Outcomes: Findings from a Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.3594openalex-snapshot
Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19
inferred← citeshttps://doi.org/10.1002/essoar.10507186.1openalex-snapshot
Pandemic Metric with Confidence (PMC) Model to Predict Trustworthy Probability of Utilized COVID-19 Pandemic Trajectory across the Global
inferred← citeshttps://doi.org/10.1002/essoar.10507444.1openalex-snapshot
Pandemic Metric with Confidence (PMC) Model to Predict Trustworthy Probability of Utilized COVID-19 Pandemic Trajectory across the Global
inferred← citeshttps://doi.org/10.1002/jmv.26625openalex-snapshot
The use of renin–angiotensin–aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID‐19 patients: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/jmv.26695openalex-snapshot
Effects of renin‐angiotensin‐aldosterone system inhibitors on disease severity and mortality in patients with COVID‐19: A meta‐analysis
inferred← citeshttps://doi.org/10.1007/978-981-97-7380-0_9openalex-snapshot
Role of ACE Inhibitors and Angiotensin Receptor Blockers in Covid19 Patients
inferred← citeshttps://doi.org/10.1007/s11906-021-01134-9openalex-snapshot
The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review
inferred← citeshttps://doi.org/10.1007/s11906-022-01207-3openalex-snapshot
Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
inferred← citeshttps://doi.org/10.1007/s12471-021-01573-8openalex-snapshot
The effects of ACE2 expression mediating pharmacotherapy in COVID-19 patients
inferred← citeshttps://doi.org/10.1007/s13410-022-01143-7openalex-snapshot
RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus
inferred← citeshttps://doi.org/10.1007/s40256-020-00439-5openalex-snapshot
Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.1007/s40292-021-00462-wopenalex-snapshot
Safety and Efficacy of Renin–Angiotensin–Aldosterone System Inhibitors in COVID-19 Population
inferred← citeshttps://doi.org/10.1016/j.acvd.2020.09.002openalex-snapshot
Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis
inferred← citeshttps://doi.org/10.1016/j.amjcard.2021.12.004openalex-snapshot
Usefulness of Combined Renin-Angiotensin System Inhibitors and Diuretic Treatment In Patients Hospitalized with COVID-19
inferred← citeshttps://doi.org/10.1016/j.bcp.2022.115370openalex-snapshot
Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic
inferred← citeshttps://doi.org/10.1016/j.cjco.2021.03.001openalex-snapshot
Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors
inferred← citeshttps://doi.org/10.1016/j.dsx.2020.06.047openalex-snapshot
The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ijcha.2020.100627openalex-snapshot
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.jiph.2021.03.004openalex-snapshot
Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study
inferred← citeshttps://doi.org/10.1016/j.jjcc.2020.07.013openalex-snapshot
COVID-19 and cardiovascular diseases
inferred← citeshttps://doi.org/10.1016/j.jjcc.2020.10.015openalex-snapshot
Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis
inferred← citeshttps://doi.org/10.1016/j.medcle.2021.04.026openalex-snapshot
Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.medcli.2021.04.005openalex-snapshot
Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis
inferred← citeshttps://doi.org/10.1038/s41440-024-01953-8openalex-snapshot
Effect of the renin–angiotensin–aldosterone system inhibitors on time to nucleic acid negative conversion in hypertensive patients with SARS-CoV-2 omicron infection: a propensity score matching study
inferred← citeshttps://doi.org/10.1055/s-0040-1715798openalex-snapshot
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine
inferred← citeshttps://doi.org/10.1055/s-010-50030openalex-snapshot
inferred← citeshttps://doi.org/10.1080/08037051.2022.2154745openalex-snapshot
Angiotensin-converting enzyme 2 in human plasma and lung tissue
inferred← citeshttps://doi.org/10.1080/10641963.2021.1963070openalex-snapshot
Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe?
inferred← citeshttps://doi.org/10.1080/14779072.2020.1826308openalex-snapshot
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1093/ajh/hpaa149openalex-snapshot
Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19
inferred← citeshttps://doi.org/10.1093/ajh/hpaa169openalex-snapshot
Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19
inferred← citeshttps://doi.org/10.1093/ajh/hpac001openalex-snapshot
Effects of Renin–Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1093/cid/ciaa1443openalex-snapshot
Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19)
inferred← citeshttps://doi.org/10.1093/cid/ciaa1592openalex-snapshot
The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.1097/ccm.0000000000005627openalex-snapshot
Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19
inferred← citeshttps://doi.org/10.1097/hjh.0000000000002784openalex-snapshot
Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies
inferred← citeshttps://doi.org/10.1097/hjh.0000000000003266openalex-snapshot
The effects of hypertension on the prognosis of coronavirus disease 2019: a systematic review and meta-analysis on the interactions with age and antihypertensive treatment
inferred← citeshttps://doi.org/10.1097/j.pbj.0000000000000085openalex-snapshot
Mortality and use of angiotensin-converting enzyme inhibitors in COVID 19 disease: a systematic review
inferred← citeshttps://doi.org/10.1097/md.0000000000025532openalex-snapshot
The therapeutic effect and safety of the drugs for COVID-19
inferred← citeshttps://doi.org/10.1097/mjt.0000000000001281openalex-snapshot
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Mortality Among COVID-19 Patients: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1101/2020.10.03.20206375openalex-snapshot
Renin Angiotensin System Inhibition and Susceptibility and Outcomes from COVID-19: A Systematic Review and Meta-analysis of 69,200 COVID-19 Patients
inferred← citeshttps://doi.org/10.1111/bcp.14660openalex-snapshot
Comparison of infection risks and clinical outcomes in patients with and without SARS‐CoV‐2 lung infection under renin–angiotensin–aldosterone system blockade: Systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1111/jch.14038openalex-snapshot
Influence of blood pressure control and application of renin‐angiotensin‐aldosterone system inhibitors on the outcomes in COVID‐19 patients with hypertension
inferred← citeshttps://doi.org/10.1111/jch.14329openalex-snapshot
Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all‐cause mortality and other clinical outcomes in patients with confirmed COVID‐19: A systemic review and meta‐analysis
inferred← citeshttps://doi.org/10.1136/bmjopen-2020-043625openalex-snapshot
Prospective meta-analysis protocol on randomised trials of renin–angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension
inferred← citeshttps://doi.org/10.1136/thoraxjnl-2020-215768openalex-snapshot
SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case-control and cohort analysis
inferred← citeshttps://doi.org/10.1155/2020/1025913openalex-snapshot
Renin‐Angiotensin System Inhibitors in COVID‐19: Current Concepts
inferred← citeshttps://doi.org/10.11606/issn.2176-7262.rmrp.2023.196221openalex-snapshot
Conhecimento fast track e orientação terapêutica: explorando as evidências relativas ao uso de inibidores do SRAA em pacientes hipertensos com COVID-19
inferred← citeshttps://doi.org/10.1161/jaha.120.021154openalex-snapshot
Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
inferred← citeshttps://doi.org/10.1161/jaha.122.025289openalex-snapshot
Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
inferred← citeshttps://doi.org/10.1177/20420986211011345openalex-snapshot
Renin–angiotensin–aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1186/s12879-021-06088-6openalex-snapshot
Comparison of renin–angiotensin–aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes
inferred← citeshttps://doi.org/10.1186/s12985-021-01526-yopenalex-snapshot
Precision therapeutic targets for COVID-19
inferred← citeshttps://doi.org/10.1186/s13643-021-01802-6openalex-snapshot
Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality
inferred← citeshttps://doi.org/10.1186/s43044-022-00303-8openalex-snapshot
Drugs acting on the renin–angiotensin–aldosterone system (RAAS) and deaths of COVID-19 patients: a systematic review and meta-analysis of observational studies
inferred← citeshttps://doi.org/10.1371/journal.pone.0239571openalex-snapshot
Association between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients
inferred← citeshttps://doi.org/10.1371/journal.pone.0275787openalex-snapshot
COVID-19 outcomes in patients taking cardioprotective medications
inferred← citeshttps://doi.org/10.14744/semb.2020.15689openalex-snapshot
The Association Between Chronic Use of Renin–Angiotensin-Aldosterone System Blockers and in-Hospital Adverse Events among COVID-19 Patients with Hypertension
inferred← citeshttps://doi.org/10.1684/stv.2020.1149openalex-snapshot
Guidance for the management of patients with vascular disease or cardiovascular risk factors and Covid-19 Position paper from VAS-European Independent Foundation in Angiology/Vascular Medicine
inferred← citeshttps://doi.org/10.18203/2320-6012.ijrms20205289openalex-snapshot
Is it an advantage or disadvantage to usage angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in COVID-19 patients?
inferred← citeshttps://doi.org/10.18316/sdh.v11i2.9853openalex-snapshot
Análise da estratégia adotada pelo Ministério da Saúde do Brasil na avaliação da qualidade metodológica dos estudos científicos sobre a COVID-19.
inferred← citeshttps://doi.org/10.21037/jxym-20-110openalex-snapshot
COVID-19 and the cardiovascular system: a systematic review of the clinical trial landscape
inferred← citeshttps://doi.org/10.21203/rs.3.rs-113824/v1openalex-snapshot
Severity of COVID-19 Infection in ACEI/ARB Users in Two Saudi Public Specialty Hospitals: Retrospective Cohort Study
inferred← citeshttps://doi.org/10.21203/rs.3.rs-345834/v1openalex-snapshot
Effect of combined renin angiotensin aldosterone inhibitors and diuretic treatment among patients hospitalized with SARS-CoV-2 Infection COVID-19
inferred← citeshttps://doi.org/10.21203/rs.3.rs-704901/v1openalex-snapshot
The Retreated Tendency of the COVID-19 Pandemic
inferred← citeshttps://doi.org/10.21203/rs.3.rs-724357/v1openalex-snapshot
Effect of ACE2 Expression Inhibiting Drugs on COVID-19 Disease Severity, Outcome and Length of Admission in Ethiopian Patients: A Causal Inference Using Marginal Structural Model with Inverse Probability Weight
inferred← citeshttps://doi.org/10.21203/rs.3.rs-783028/v1openalex-snapshot
Pandemic Metric with Confidence (PMC) Model to Predict Trustworthy Probability of Utilized COVID-19 Pandemic Trajectory across the Global
inferred← citeshttps://doi.org/10.2174/1573402118666220407093332openalex-snapshot
ACEi/ ARB and Deaths of COVID-19 Patients
inferred← citeshttps://doi.org/10.22270/ajprd.v9i1.910openalex-snapshot
Covid-19: A Pharmacotherapeutic Perspective
inferred← citeshttps://doi.org/10.23736/s0026-4725.20.05271-8openalex-snapshot
Relationship between angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and SARS-CoV-2 infection: where are we?
inferred← citeshttps://doi.org/10.30824/2103-1openalex-snapshot
Women in Hypertension Research Committee:Goals and Launch of the WiHR Network
inferred← citeshttps://doi.org/10.30824/2103-9openalex-snapshot
An ISH-led prospective meta-analysis on RCTs of RAAS inhibitors in COVID-19 patients: A call for collaboration
inferred← citeshttps://doi.org/10.3389/fcvm.2021.609857openalex-snapshot
Associations Between the Use of Renin–Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies
inferred← citeshttps://doi.org/10.3389/fendo.2023.1077959openalex-snapshot
RAAS inhibitors are associated with a better chance of surviving of inpatients with Covid-19 without a diagnosis of diabetes mellitus, compared with similar patients who did not require antihypertensive therapy or were treated with other antihypertensives
inferred← citeshttps://doi.org/10.3389/fmed.2021.703661openalex-snapshot
Mortality and Severity in COVID-19 Patients on ACEIs and ARBs—A Systematic Review, Meta-Analysis, and Meta-Regression Analysis
inferred← citeshttps://doi.org/10.3389/fphys.2021.624052openalex-snapshot
Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic
inferred← citeshttps://doi.org/10.3390/arm93010004openalex-snapshot
A Meta-Analysis of the Impact of Using Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin II Receptor Blockers (ARBs) on Mortality, Severity, and Healthcare Resource Utilization in Patients with COVID-19
inferred← citeshttps://doi.org/10.3390/diagnostics10080548openalex-snapshot
Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension
inferred← citeshttps://doi.org/10.3390/ijms232214340openalex-snapshot
Targeting the Complement–Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy
inferred← citeshttps://doi.org/10.3390/jcm10245812openalex-snapshot
Comparison between Dexamethasone and Methylprednisolone Therapy in Patients with COVID-19 Pneumonia Admitted to Non-Intensive Medical Units
inferred← citeshttps://doi.org/10.3390/jcm9082506openalex-snapshot
COVID-19 and the Kidney: From Epidemiology to Clinical Practice
inferred← citeshttps://doi.org/10.3390/ph15060739openalex-snapshot
Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?
inferred← citeshttps://doi.org/10.34172/apb.2022.001openalex-snapshot
Renin Angiotensin System and Covid-19 Infection
inferred← citeshttps://doi.org/10.4103/ajim.ajim_91_22openalex-snapshot
A Study of Prognosis and Outcome of COVID-19-Infected Hypertensive Patients on Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
inferred← citeshttps://doi.org/10.47176/mjiri.36.135openalex-snapshot
Soluble ACE2 as a Risk or Prognostic Factor in COVID-19 Patients: A Cross-sectional Study
inferred← citeshttps://doi.org/10.47611/jsr.v10i4.1401openalex-snapshot
RAAS inhibitors for hypertensive patients during Covid-19 infection – a metanalysis
inferred← citeshttps://doi.org/10.5603/ah.a2020.0013openalex-snapshot
Severity of SARS-COV-2 infection and angiotensin converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis
inferred← citeshttps://doi.org/10.6061/clinics/2021/e2342openalex-snapshot
Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review
inferred← citeshttps://doi.org/10.6084/m9.figshare.14337691openalex-snapshot
Additional file 1 of Precision therapeutic targets for COVID-19
inferred← citeshttps://doi.org/10.6084/m9.figshare.16575507openalex-snapshot
Additional file 1 of Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality
inferred← citeshttps://doi.org/10.6084/m9.figshare.16575510openalex-snapshot
Additional file 2 of Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality
inferred← citeshttps://doi.org/10.6084/m9.figshare.21019171openalex-snapshot
Additional file 1 of Drugs acting on the renin–angiotensin–aldosterone system (RAAS) and deaths of COVID-19 patients: a systematic review and meta-analysis of observational studies
inferred← citeshttps://doi.org/10.7326/l20-0887openalex-snapshot
Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
inferred← citeshttps://doi.org/10.7326/l20-0969openalex-snapshot
Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
inferred← citeshttps://doi.org/10.7326/l20-1446openalex-snapshot
Update Alert 7: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.